Back to top

cell-therapy: Archive

Zacks Equity Research

FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.

JNJPositive Net Change SRPTNegative Net Change CORTNegative Net Change FGENNegative Net Change

Zacks Equity Research

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

DVAXPositive Net Change JNJPositive Net Change AGENNegative Net Change CORTNegative Net Change

Zacks Equity Research

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

RHHBYNegative Net Change MRKNegative Net Change RCUSPositive Net Change ITOSNegative Net Change

Zacks Equity Research

Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal

Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.

ALGNNegative Net Change HAEPositive Net Change BRKRNegative Net Change SIBNPositive Net Change